Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.

Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. See our latest analysis for Quest Diagnostics. The analyst upgrade and WHOOP partnership come on top of strong momentum in Quest Diagnostics, with the share price at $241.76 and a 30 day share price return of 16.42%. The year to date share price return of 39.11% and...

Quest Diagnostics stock has delivered a strong 3 year return, yet the current checks present a more nuanced picture, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair. Quest Diagnostics has returned 92.2% over the past 3 years, which puts extra focus on whether recent gains are already pricing in its cash flow potential. The expansion of WHOOP Advanced Labs, powered in the U.S. by Quest Diagnostics, can...

Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.

EYE beats Q2 earnings and revenue estimates, expands operating margin and raises its 2026 profit outlook despite gross margin pressure.

Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.

HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.

ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.

LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.

Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.

Prestige Consumer's Q1 earnings and revenues outpace estimates as acquisitions boost its fiscal 2027 outlook despite margin pressure.

Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.

LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.

BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.

STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.

Quest Diagnostics (DGX) has drawn fresh attention after raising its full year 2026 revenue and earnings guidance, alongside reporting second quarter results that showed higher sales and net income versus the prior year. See our latest analysis for Quest Diagnostics. Quest Diagnostics shares have climbed strongly over 2026 so far, with a year to date share price return of 34.48% and a 90 day share price return of 23.58%. That momentum sits alongside a 1 year total shareholder return of 37.26%...

DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.

ZBH beats second-quarter earnings and revenue estimates, raises its 2026 outlook and gains in pre-market despite pressure on adjusted margins.

Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.

CVS beats Q2 earnings and revenue estimates as stronger segment performance lifts results and prompts raised 2026 guidance, sending shares higher.

Quest Diagnostics stock has climbed strongly over the past few years, yet current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach. Quest Diagnostics has returned 83.7% over the past 3 years, which means anyone who held through that period already saw a substantial gain and now needs to judge how much value is left in the current price. Recent strong demand for higher value diagnostic services can support...

Samples—and a certain stink—are accumulating at Quest Diagnostics thanks to the cyclosporiasis outbreak. “You get used to it.”

IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.

Henry Schein tops Q2 earnings and revenue estimates as internal sales growth accelerates and management raises its 2026 outlook, lifting shares.

DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project costs could temper the payoff.

Credo Technology leads Zacks' latest market-beating highlights as strong stock gains and portfolio performance stand out despite a mixed U.S. economy.

Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.

The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.

DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.

Labcorp's Q2 earnings and revenues surpass estimates, margins expand, and its 2026 outlook is raised, but shares fall 6% in pre-market trading.

By Sahil Pandey July 30 (Reuters) - Laboratory operator Labcorp raised its annual profit forecast and posted better-than-expected second-quarter results on Thursday, ‌as steady demand for diagnostic testing and growth in ‌its drug-development services business boosted performance. Shares of the company fell about 6% in ​premarket trading.

BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.

The company raised its outlook on booming AI demand, but the stock is telling a different story by standing still.

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 117 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Up

Demand for medical testing services is rising.

Earlier this week, Quest Diagnostics reported second-quarter 2026 results showing sales of US$3,043 million and diluted EPS of US$2.84, and raised its full‑year 2026 revenue guidance to US$11.95–US$12.05 billion and reported EPS to US$9.97–US$10.17. The company also continued its long-running capital return program, repurchasing 522,436 shares for US$100 million in the quarter, which supports earnings per share alongside higher‑value advanced diagnostics and growing test volumes. We’ll now...

Quest Diagnostics is back in focus after analysts lifted Fair Value estimates from US$223.44 to US$239.38, a move that has coincided with price targets shifting into the US$245 to US$265 range for more bullish views and into the low US$230s for more cautious ones. These adjustments reflect how analysts are weighing the Q2 beat, higher full year guidance, and ongoing volume and margin debates when refreshing their models. Read on to see what is driving this evolving narrative and how you can...

Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Moby summary of Quest Diagnostics Incorporated's Q2 2026 earnings call

Quest Diagnostics Inc (DGX) reports robust financial performance with a 10% revenue increase, while navigating operational headwinds and strategic investments.

Quest Diagnostics (NYSE:DGX) reported double-digit revenue growth and raised its full-year 2026 outlook after what executives described as strong demand across its physician, hospital and consumer channels, as well as increased volume from major collaborations with Corewell Health and Fresenius Medi

Quest Diagnostics put up a definitive beat Thursday, driven by solid demand across its consumer division, leading the stock to surge.

Here is how Corcept Therapeutics (CORT) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.

Quest Diagnostics shares rise as second-quarter earnings and revenues beat estimates, testing demand surges and the company raises its 2026 outlook.

Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $3.04 billion. Its non-GAAP profit of $3.12 per share was 10.5% above analysts’ consensus estimates.

Quest Diagnostics (DGX) delivered earnings and revenue surprises of +11.03% and +2.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?